
Bromelain for knee osteoarthritis: a negative placebo trial and weaker comparisons
Bromelain studies include a negative placebo-controlled trial and active comparisons that cannot establish equivalent osteoarthritis relief.
Bromelain has not shown dependable benefit over placebo for knee osteoarthritis, and pineapple-enzyme marketing exceeds the clinical evidence.
Pineapple familiarity is not clinical proof
Bromelain is a mixture of protein-digesting enzymes derived from pineapple stems or fruit. Its food origin and laboratory anti-inflammatory actions make an appealing marketing story, but eating pineapple is not equivalent to taking a characterized enzyme preparation. Oral products vary in enzyme activity, amount, coatings and added ingredients.
A mechanism can justify a trial without predicting its result. Osteoarthritis outcomes must be measured in people with the condition, using pain and function scales and an appropriate control. A change in an inflammatory marker or enzyme absorption does not by itself establish easier walking or less knee pain.

The placebo-controlled pilot was negative
A randomized double-blind study assigned 47 people with moderate-to-severe knee osteoarthritis to 800 milligrams of bromelain daily or placebo for 12 weeks. Only 31 completed the study. Total WOMAC, subscale and quality-of-life outcomes did not differ significantly between groups, although both groups improved on one disability measure.
The small sample and high dropout made the estimate imprecise, so the trial did not prove that bromelain can never help. It did fail to demonstrate the expected advantage. Describing the study as merely underpowered while ignoring the negative result would give the hypothesis more certainty than the data support.
Active comparisons answer a weaker question
A later pilot compared bromelain with diclofenac in 40 people with mild-to-moderate knee osteoarthritis. Both groups improved and did not differ on WOMAC or quality-of-life scores after four weeks. Because there was no placebo group and the study was single blind, the result cannot establish that bromelain itself caused improvement.
Failure to detect a difference is also not proof of equivalence unless a study uses a prespecified noninferiority margin and adequate sample size. A small active-comparator trial may miss a meaningful difference. Marketing that calls bromelain “as effective as” a medicine therefore overstates what this design established.
A broad pain meta-analysis is not knee-specific proof
A 2023 systematic review combined bromelain research across several clinical uses and found a small average pain reduction. The included conditions, preparations and comparators varied. A pooled pain result across different problems should not override the direct placebo-controlled knee trial or be presented as a precise osteoarthritis estimate.
Reviews can identify a research signal while still leaving product and diagnosis uncertainty. Readers should check how many participants actually had knee osteoarthritis, whether bromelain was used alone, and whether the control was placebo, usual care or an active medicine.

Safety and product activity require review
Reported adverse effects include nausea, diarrhea, headache and other gastrointestinal symptoms. Bromelain may affect bleeding and could interact with anticoagulant or antiplatelet medicines. Pineapple allergy and cross-reactivity are also relevant. The actual label should be reviewed before use rather than relying on the general safety of pineapple as food.
Enzyme products may state milligrams without a meaningful activity measure, making trial matching difficult. A blend with turmeric or other enzymes adds attribution problems. Manufacturing quality can establish identity and contamination control, but it cannot prove the supplement relieves osteoarthritis.
The evidence supports restraint
Bromelain has not been shown to rebuild cartilage, slow structural progression or replace supported care. The most direct placebo trial did not demonstrate symptom benefit, while favorable comparisons have important design limits. That record supports further rigorous research rather than confident retail claims.
A future trial should be large, preregistered and use a chemically characterized preparation with a patient-important primary outcome. Until then, consumers should treat bromelain as an unproven candidate and avoid delaying assessment of persistent swelling, injury or worsening symptoms.
A personal response would not settle efficacy
Someone may feel better after starting bromelain, but an individual sequence cannot separate supplement effect from symptom fluctuation, changed activity, expectation or concurrent treatment. That uncertainty is not a reason to dismiss the experience; it is a reason to avoid turning it into a universal claim. Recording a baseline and a review date is more informative than relying on memory.
A defined stop rule also limits indefinite use of an unproven product. If the goal is not met, increasing the amount can add risk without evidence. If improvement occurs, the person and clinician can still ask whether the change is large enough to justify cost and exposure. This disciplined approach respects both the negative trial and the remaining uncertainty.
Sources & further reading
This article provides educational information. Ask a qualified clinician or pharmacist about your symptoms, medical conditions, medicines and supplement interactions.